Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

The active ingredient is a polysaccharide from N. meningitidis group C linked to the diphtheria toxoid CRM197. This conjugation creates a T‑cell‑dependent antigen that stimulates the immune system to produce high‑affinity anti‑capsular antibodies and develop immunologic memory, providing active protection against serogroup C infection.

The dosing schedule for Menjugate is determined by the prescribing health professional based on age, previous vaccination history and local immunization guidelines. The prescriber selects the appropriate number of doses and intervals to achieve optimal protection.

Data on Menjugate use in pregnancy are limited. It should be administered only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding is not a contraindication, but the decision should be made in consultation with a health‑care provider.

To order Menjugate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Menjugate is a conjugate vaccine that uses the CRM197 carrier protein, similar to other licensed group C conjugates such as Menactra or Menveo. All provide T‑cell‑dependent immunity, but differences may exist in dosing schedules, carrier proteins and regional licensing. Clinical efficacy is comparable when administered according to approved regimens.

Menjugate must be stored at 2 °C to 8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Menjugate is given by intramuscular injection, typically into the deltoid muscle of the upper arm. The exact schedule (number of doses and intervals) is defined by national immunization programs and the prescribing clinician, with booster doses recommended for certain age groups.

The most serious adverse events reported are severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome (very rare), high‑grade fever, seizures and hypotension. Any signs of a severe reaction require immediate medical attention.

Menjugate should not be given to individuals with a known severe hypersensitivity to any component of the vaccine, including the CRM197 carrier protein. Persons who have experienced a previous severe allergic reaction to a meningococcal conjugate vaccine should also avoid it.